|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Azilsartan kamedoxomil#Clinical Studies]] |
| {{Azilsartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| The antihypertensive effects of Edarbi have been demonstrated in a total of seven double-blind, randomized studies, which included five placebo-controlled and four active comparator-controlled studies (not mutually exclusive). The studies ranged from six weeks to six months in duration, at doses ranging from 20 mg to 80 mg once daily. A total of 5941 patients (3672 given Edarbi, 801 given placebo, and 1468 given active comparator) with mild, moderate or severe [[hypertension]] were studied. Overall, 51% of patients were male and 26% were 65 years or older; 67% were white and 19% were black.
| |
| | |
| Two 6-week, randomized, double-blind studies compared the effect on blood pressure of Edarbi at doses of 40 mg and 80 mg, with placebo and with active comparators. Blood pressure reductions compared to placebo based on clinic blood pressure measurements at trough and 24-hour mean blood pressure by ambulatory blood pressure monitoring (ABPM) are shown in Table 1 for both studies. Edarbi, 80 mg, was statistically superior to placebo and active comparators for both clinic and 24-hour mean blood pressure measurements.
| |
| | |
| {|
| |
| |[[File:Azilsartan05.jpg|thumb|800px]]
| |
| |}
| |
| | |
| In a study comparing Edarbi to valsartan over 24 weeks, similar results were observed.
| |
| | |
| Most of the antihypertensive effect occurs within the first two weeks of dosing.
| |
| | |
| Figure 2 shows the 24-hour ambulatory systolic and diastolic blood pressure profiles at endpoint.
| |
| | |
| {|
| |
| |[[File:Azilsartan06.jpg|thumb|800px]]
| |
| |}
| |
| | |
| {|
| |
| |[[File:Azilsartan07.jpg|thumb|800px]]
| |
| |}
| |
| | |
| Other studies showed similar 24-hour ambulatory blood pressure profiles.
| |
| | |
| Edarbi has a sustained and consistent antihypertensive effect during long-term treatment, as shown in a study that randomized patients to placebo or continued Edarbi after 26 weeks. No rebound effect was observed following the abrupt cessation of Edarbi therapy.
| |
| | |
| Edarbi was effective in reducing blood pressure regardless of the age, gender, or race of patients, but the effect, as monotherapy, was smaller, approximately half, in black patients, who tend to have low renin levels. This has been generally true for other angiotensin II antagonists and ACE inhibitors.
| |
| | |
| Edarbi has about its usual blood pressure lowering effect size when added to a calcium channel blocker (amlodipine) or a thiazide-type diuretic (chlorthalidone).
| |
| | |
| There are no trials of Edarbi demonstrating reductions in cardiovascular risk in patients with [[hypertension]], but at least one pharmacologically similar drug has demonstrated such benefits.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = EDARBI (AZILSARTAN KAMEDOXOMIL) TABLET [TAKEDA PHARMACEUTICALS AMERICA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b16bfc-38c1-4133-bd7d-13258d54edec | publisher = | date = | accessdate = 19 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Benzimidazoles]]
| |
| [[Category:Carbamates]]
| |
| [[Category:Ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |